Pathology: mHCC - 1st line (L1);
| mHCC - 1st line (L1) | |||||
| IMbrave-150, 2020 | CheckMate 459, 2019 | LEAP 002, 0 | ORIENT-32, 2021 | ||
| pembrolizumab plus lenvatinib | 1 | T1 | |||
| sintilimab | 1 | T1 | |||
| atezolizumab plus bevacizumab | 1 | T1 | |||
| nivolumab alone | 1 | T1 | |||
| lenvatinib | 0 | T0 | |||
| sorafenib | 0 | T0 | T0 | T0 | |